Top
US_Flag An official website of the United States government Here's how you know
GOV

The .gov means it's official.

Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

LOCK

The site is secure.

The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

 
U.S. Food & Drug Administration
Continuing Education and Accreditation
Division of Learning and Organizational Development
Center for Drug Evaluation and Research

Naltrexone Injection for Opioid Use Disorder - FDA’s Efforts to Reduce Medication Errors

Enroll
Step Status
Educational Content ✘
Posttest ✘
Evaluation ✘
Starts On: Tue, 11/28/23: 12:00 AM EST
Ends On: Fri, 11/27/26: 12:00 AM EST
Type: Enduring Material
Credits: 1
Description: This activity will focus on the importance of medications used for opioid use disorder and provide an overview of FDA's postmarket surveillance process related to medication errors. The presenters will discuss medication errors identified for naltrexone injectable suspension, actions to mitigate those errors, and will highlight the importance of the healthcare provider's role in drug safety.
Objectives:
  • Discuss the opioid crisis and importance of medications used to treat opioid use disorder.
  • Describe an overview of postmarket drug safety and postmarket surveillance.
  • Illustrate how FDA’s process for identifying and evaluating postmarket safety issues was applied for medication errors.
  • Recognize how postmarket safety information can be used to change product labeling.
  • Summarize how healthcare providers can contribute to drug safety within their practice.
Additional Information: Review the Activity Announcement for additional details: Announcement Form

Slides:
Additional Resources: SLIDES